Lisa Dalton
Net worth: 517 $ as of 2023-07-30
Profile
Lisa Dalton served as the Head of Human Resources at Spark Therapeutics, Inc. from 2014 to 2019.
Prior to that, she was the Vice President of Human Resources at Shire Pharmaceuticals, Inc. She also served as an Independent Director at Nabriva Therapeutics Plc from 2021 to 2023.
Dalton received an undergraduate degree from The Pennsylvania State University and an MBA from Rutgers Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NABRIVA THERAPEUTICS PLC
0.01% | 2023-01-30 | 364 ( 0.01% ) | 517 $ | 2023-07-30 |
Former positions of Lisa Dalton
Companies | Position | End |
---|---|---|
NABRIVA THERAPEUTICS PLC | Director/Board Member | 2023-07-29 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Human Resources Officer | - |
SPARK THERAPEUTICS, INC. | Human Resources Officer | - |
Training of Lisa Dalton
The Pennsylvania State University | Undergraduate Degree |
Rutgers Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Nabriva Therapeutics Plc |
- Stock Market
- Insiders
- Lisa Dalton